REGENXBIO reports Q4 net loss $51.2M; BLA for RGX-121 submitted, Nippon Shinyaku partnership closed

REGENXBIO Inc.

Net loss $51.2M ($1.01/sh) in Q4 2024 vs $62.9M; full year $227.1M ($4.59/sh) vs $263.5M. Revenue $83.3M vs $90.2M.
BLA for RGX-121 (MPS II) submitted; FDA approval expected 2H 2025. Nippon Shinyaku deal closed: $110M upfront, up to $700M milestones.
RGX-202 Duchenne pivotal trial nearly 50% enrolled; completion expected 2025, BLA mid-2026. Phase I/II data show favorable safety and functional improvement.
Cash and securities $244.9M at Dec 31, 2024 (vs $314.1M). With $110M Nippon upfront, cash runway into 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.